3/31
08:16 am
gnlx
Genelux Co. (NASDAQ: GNLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
High
Report
Genelux Co. (NASDAQ: GNLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
3/28
04:10 pm
gnlx
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
High
Report
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
3/25
11:58 am
gnlx
Genelux Co. (NASDAQ: GNLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
Genelux Co. (NASDAQ: GNLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
3/25
08:52 am
gnlx
Genelux prices 3M shares at $3.50 in underwritten public offering [Seeking Alpha]
Medium
Report
Genelux prices 3M shares at $3.50 in underwritten public offering [Seeking Alpha]
3/25
08:31 am
gnlx
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
Medium
Report
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
3/25
08:30 am
gnlx
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
High
Report
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
3/25
08:30 am
gnlx
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease
High
Report
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease
2/3
06:45 am
gnlx
Genelux Corporation Announces New Chief Financial Officer
Medium
Report
Genelux Corporation Announces New Chief Financial Officer